Soligenix (SNGX) Enterprise Value (2010 - 2026)
Soligenix's (SNGX) quarterly Enterprise Value came in at -$6.0 million in Q1 2026, up 17.37% YoY from -$5.1 million in Q1 2025, and up 24.03% on a QoQ basis from -$7.9 million in Q4 2025.
Soligenix (SNGX) Enterprise Value (2010 - 2026) Analysis & Trends
Soligenix (SNGX) has 17 years of Enterprise Value data on file, last reported at -$6.0 million in Q1 2026.
- Quarterly Enterprise Value rose 17.37% year-over-year to -$6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.0 million (up 17.37% YoY) and the FY2025 annual result came in at -$7.9 million, down 1.49% from the prior year.
- Enterprise Value improved to -$6.0 million in Q1 2026, from -$7.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$5.1 million in Q2 2025 to a low of -$22.9 million in Q1 2022.
- A 5-year average of -$11.0 million and a median of -$9.8 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2023 — Enterprise Value jumped 55.12% — and 2025, when it fell 6.96%.
- Tracing SNGX's Enterprise Value over 5 years: stood at -$13.4 million in 2022, then jumped by 36.78% to -$8.4 million in 2023, then gained by 7.42% to -$7.8 million in 2024, then retreated by 1.49% to -$7.9 million in 2025, then increased by 24.03% to -$6.0 million in 2026.
- The last three Enterprise Value figures came in at -$6.0 million (Q1 2026), -$7.9 million (Q4 2025), and -$10.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - | -9.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.81 Mn |
| Mar 31, 2026 | -6.03 Mn |
| Dec 31, 2025 | -7.94 Mn |
| Sep 30, 2025 | -10.53 Mn |
| Jun 30, 2025 | -5.10 Mn |
| Mar 31, 2025 | -7.30 Mn |
| Dec 31, 2024 | -7.82 Mn |
| Sep 30, 2024 | -9.84 Mn |
| Jun 30, 2024 | -9.41 Mn |
| Mar 31, 2024 | -7.09 Mn |
| Dec 31, 2023 | -8.45 Mn |
| Sep 30, 2023 | -10.30 Mn |
| Jun 30, 2023 | -13.16 Mn |
| Mar 31, 2023 | -10.27 Mn |
| Dec 31, 2022 | -13.36 Mn |
| Sep 30, 2022 | -16.87 Mn |
| Jun 30, 2022 | -20.16 Mn |
| Mar 31, 2022 | -22.88 Mn |
| Dec 31, 2021 | -26.04 Mn |
| Sep 30, 2021 | -28.87 Mn |